Paper of the Day - no rheumatoid arthritis drug stands out

23 Nov 07

But the authors have panned the quality of the available head-to-head evidence, with only 143 trials from the inital 2,395 eligible to be included in the review. Very few trials looked at longer term outcomes in patients typically seen in the community.

They found no clinically significant difference among the conventional DMARDs studied - methotrexate, leflunomide or sulfasalazine – or among the biologic therapies – adalimumab, etanercept or infliximab.

Annals of Internal Medicine 2007 20 November early online publication.